{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:24:03Z","timestamp":1774977843304,"version":"3.50.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAR"],"published-print":{"date-parts":[[2026,3,30]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Alzheimer\u2019s Disease (AD) is a major global challenge and the most common cause of\ndementia worldwide. Accumulation of Amyloid-Beta (A\u03b2) is considered a key factor in AD pathophysiology\nand progression, and is linked to disruptions of neuronal integrity and the initiation of\nseveral downstream neurodegenerative cascades. Immunotherapeutic agents targeting A\u03b2 have\nemerged as potential disease-modifying drug candidates, and extensive efforts have been dedicated\nto both active and passive modalities. Early A\u03b2 vaccines demonstrated proof of concept; however,\nthey were later discontinued due to several safety concerns, which, in turn, guided the refinement of\nepitope design and immune response modulation in the second-generation ones. On the other hand,\nearly monoclonal antibodies have also faced challenges, such as variable efficacy and adverse\nevents, particularly Amyloid-Related Imaging Abnormalities (ARIA), which ultimately led to their\ndiscontinuation. Nonetheless, recent regulatory advances have led to the approvals of Aduhelm\u00ae\n(Aducanumab), Leqembi\u00ae (Lecanemab), and Kisunla\u00ae (Donanemab), each of which has demonstrated\nthe ability to reduce A\u03b2 burden and slow cognitive decline. Despite these advancements,\nchallenges persist regarding patient selection, biomarker-guided monitoring, ARIA risk reduction,\nlong-term outcomes, and global accessibility. Notably, the clinical benefits observed to date remain\nmodest, and it remains uncertain whether the currently approved A\u03b2-targeted immunotherapies\nachieve meaningful long-term disease modification. Collectively, the evolution of A\u03b2-targeted immunotherapies\nhas provided further insights into the complexity of AD pathology and the challenges\nassociated with future progress toward achieving effective disease modification. This paper aims to\nprovide a comprehensive review of all A\u03b2-directed immunotherapies, both active and passive\nagents, that have advanced into clinical trials, including those currently approved, discontinued, or\nundergoing late-stage evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115672050468315260226041235","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:38:02Z","timestamp":1774975082000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Amyloid-Beta Immunotherapies for Alzheimer\u2019s Disease: Current\nProgress"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7128-4720","authenticated-orcid":true,"given":"Firas H.","family":"Bazzari","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Jerash University, Jerash 26150, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-795X","authenticated-orcid":true,"given":"Amjad H.","family":"Bazzari","sequence":"additional","affiliation":[{"name":"Department of Basic Scientific Sciences, Faculty of Science, Applied Science Private University, Amman 11931, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Alzheimer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672050468315260226041235","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/251671\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672050468315260226041235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:38:31Z","timestamp":1774975111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/251671\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115672050468315260226041235","relation":{},"ISSN":["1567-2050"],"issn-type":[{"value":"1567-2050","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}